期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乙酰肝素酶在糖尿病肾病患者肾组织的表达及临床意义 被引量：2

原文传递
导出
摘要 硫酸乙酰肝素（HS）对维持肾小球基底膜（GBM）的电荷屏障起关键作用。近年来乙酰肝素酶（HPA）被认为可能是导致肾脏蛋白尿疾病HS减少的机制之一，而目前有关HPA在糖尿病肾病（DN）患者肾组织表达水平及部位的相关研究，国内外鲜有报道。本研究采用免疫组化技术观察DN患者肾组织的HPA表达，分析其与蛋白尿、肾功能等的相关性，以探讨DN的发生发展机制，为临床防治DN提供理论依据。
作者 唐琳 刘章锁 窦艳娜 周雅丽 刘东伟
机构地区 郑州大学第一附属医院肾内科
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2008年第11期845-846,共2页 Chinese Journal of Nephrology
基金 河南省自然科学基金（72300450160） 河南省医学科技攻关计划项目（20060031） 河南省教育厅自然科学研究项目（2007320059）
关键词 糖尿病肾病患者 肾组织表达 乙酰肝素酶 临床意义 肾小球基底膜 硫酸乙酰肝素 免疫组化技术 发生发展机制
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献7

  • 1Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev, 2001, 17: 412-421.
  • 2Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med, 1999, 5: 793-802.
  • 3Jeansson M, Haraldsson B. Glomerular size and charge selectivity in the mouse after exposure to glycosaminoglycandegrading enzymes. J Am Soc Nephrol, 2003, 14: 1756- 1765.
  • 4唐琳,王玉华,刘章锁,肖静,窦艳娜,董吉.乙酰肝素酶在糖尿病肾病大鼠蛋白尿发生中的作用[J].中华肾脏病杂志,2008,24(4):277-281. 被引量：4
  • 5Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes, 2005, 54: 2172- 2178
  • 6van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic: nephropathy. Kidney Int, 2006, 70: 2100-2108.
  • 7Wijnhoven TJ, den Hoven M J, Ding H, et al. Heparanase induces a difterential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia, 2008, 51: 372-382.

二级参考文献12

  • 1Jeansson M, Haraldsson B. Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycandegrading enzymes. J Am Soc Nephrol, 2003,14:1756-1765.
  • 2Conde-Knape K. Heparan sulfate proteoglyeans in experimental models of diabetes: a role for perleean in diabetes complications. Diabetes Metab Res Rev,2001,17: 412-421.
  • 3Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med, 1999,5:793-802.
  • 4Levidiotis V, Freeman C, Punler M, et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol, 2004,15:2882-2892.
  • 5Levidiotis V, Kanellis J, Ierino FL, et ah Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney lnt, 2001,60:1287-1296.
  • 6Levidiotis V, Freeman C, Tikellis C, et al. Heparanase inhibition reduces proteinuria in a model of accelerated antiglomerular basement membrane antibody disease. Nephrology (Carlton), 2005,10:167-173.
  • 7Katz A, Van-Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J, 2002,4:996-1002.
  • 8Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun, 2006,341:958-963.
  • 9van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int, 2006,70:2100-2108.
  • 10Han J, Mandal AK, Hiebert LM. Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor. Cardiovasc Diabetol, 2005,4:12.

共引文献3

同被引文献30

  • 1韩从华,龚时鹏.低分子肝素钠治疗糖尿病肾病临床疗效评价[J].实用医技杂志,2006,13(14):2449-2450. 被引量：2
  • 2Hook M,Wasteson A,Oldberg A. A heparan sulfate degrading endoglycosidase from rat liver tissue[J]. Biochem Biophys Res Commun, 1975,67(4) : 1422-1428.
  • 3Freeman C,Parish C R. A rapid quantitative assay for the de tection of mammalian heparanase activity[J]. Biochem J, 1997, 32:229 237.
  • 4Vlodavsky I,Friedmann Y, Elkin M, et al. Mammalian hepara- nasc:gene cloning, expression and function in tumor progres sion and metastasis[J]. Nat Med, 1999,5 (7): 793-802.
  • 5Hulel M D, Freeman C, Hamdori B J, el al. Cloning of mamma lian heparanase, an important enzyme in tumor invasion and met aslasis[J]. Nat Med, 1999,5 (7) : 803-809.
  • 6Toyoshima M, Nakajima M. Human heparanase[J]. J Biol Chem, 1999,274 (34) :2413-2416.
  • 7l.evy Adam F, Miao H Q, Heinrikson R L, et al. Heterodimer formation is essential for heparanase enzymatic activity [J ]. Biochem Biophys Res Commun, 2003,308 ( 4 ):885-891.
  • 8Marchctti D, Reiland J, Erwin B, et al, Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin ana- logues[J]. Int J Cancer,2003,104(2) :167-174.
  • 9van den Hoven M J, Rops A L, Bakker M A, et al. Increased expression of heparanase in overt diabetic ncphropathy[J]. Kidney Int,2006,70(12) :2100-2108.
  • 10Levidiotis V,Kanellis J, lerino F l.,et al. Increased expression of heparanase in puromycin aminonucleoside nephrosis[J]. Kidney Int,2001,60(4) :1287-1296.

引证文献2

二级引证文献2

中华肾脏病杂志
2008年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部